Back to results
US 11,028,077 B2Granted
Crystalline pharmaceutical and methods of preparation and use thereof
AssigneeNovartis Pharmaceuticals Corporation
InventorsJohn Burnier, Thomas Gadek, Frederic Naud
Life of this patent
Estimating the term…
Abstract
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Claims17
A crystalline form of the compound of Formula I:
- or a pharmaceutically acceptable salt thereof, having an X-ray powder diffraction pattern comprising the following peaks, in terms of 2θ, of about 18.2°, 21.4° and 22.7°.
A crystalline form of the compound of Formula I:
- or a pharmaceutically acceptable salt thereof, having a differential scanning calorimetry thermogram comprising an endothermic peak at about 145° C.
A crystalline form of the compound of Formula I:
- or a pharmaceutically acceptable salt thereof, having a thermogravimetric analysis spectrum comprising a mass loss of about 2.5% between room temperature and 180° C.
A crystalline form of the compound of Formula I:
- or a pharmaceutically acceptable salt thereof, having a Raman chromatograph substantially as shown in FIG. 5.
Dependencies are inferred from the claim text.